Drug Profile
Dihydroartemisinin/piperaquine - Chongqing Holley Holding/Medicines for Malaria Venture/Oxford University/Sigma-tau SpA
Alternative Names: Artekin; Eurartekin; Eurartesim; Piperaquine/dihydroartemisininLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Chongqing Holley; Medicines for Malaria Venture; sigma-tau SpA; University of Oxford
- Developer Medicines for Malaria Venture; sigma-tau SpA
- Class Antimalarials; Artemisinins; Piperazines; Quinolines; Sesquiterpenes
- Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Protein synthesis inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Malaria
Most Recent Events
- 19 Feb 2021 The Medicines for Malaria Venture announces intention to submit MAA to the EMA for Malaria (In neonates, In infants, In adolescents)
- 12 Oct 2018 No recent reports on development identified - Phase-II for Malaria (In infants) in Congo, Gambia, Mozambique, Burkina Faso, Tanzania (PO, Fast dissolve)
- 08 Jul 2015 Sigma-tau SpA completes its phase II trial in Malaria (In infants) in Tanzania, Congo, Mozambique, Gambia and Burkina Faso (NCT01992900)